A7RC peptide modified paclitaxel liposomes dually target breast cancer (original) (raw)
Ran Wang,b Ning Gao,bc Minghui Li,b Xuyu Tian,bd Weili Yang,b Ying Ruan,b Chunlan Zhou,b Guangtian Wang,b Xiaoying Liu,b Shukun Tang,b Yan Yu,a Ying Liu,a Guangyu Sun,a Haisheng Peng*be and Qun Wang*e
* Corresponding authors
a Department of Medical Oncology, The Tumor Hospital of Harbin Medical University, 150 Hapin Road, Harbin, China
b Department of Pharmaceutics, Daqing Campus, Harbin Medical University, 1 Xin Yang Road, Daqing, China
c Department of Pharmaceutics, Harbin Commercial University, 138 Tong Da Street, Harbin, China
d Department of NMR, Daqing Oilfield General Hospital, 9 Zhong Kang Road, Daqing, China
e Department of Chemical and Biological Engineering, Iowa State University, Ames, IA 50011, USA
E-mail: fisher1688@163.com, qunwang@iastate.edu
Fax: +86-459-8977 588, +(515) 294-8216
Tel: +86-459-8153 003, +(515) 294-4218
Abstract
A7R peptide (ATWLPPR), a ligand of the NRP-1 receptor, regulates the intracellular signal transduction related to tumor vascularization and tumor growth. Here, we designed A7R-cysteine peptide (A7RC) surface modified paclitaxel liposomes (A7RC-LIPs) to achieve targeting delivery and inhibition of tumor growth and angiogenesis simultaneously. The cytotoxicity, inhibiting angiogenesis, and internalization of various liposomes by cells were assessed in vitro to confirm the influence of the peptide modification. The accumulations of A7RC-LIPs in various xenografts in mice were tracked to further identify the function of the peptide on the liposomes’ surface. The results confirmed that A7RC peptides could enhance the uptake of vesicles by MDA-MB-231 cells, leading to stronger cytotoxicity in vitro and higher accumulation of vesicles in MDA-MB-231 xenografts in vivo. In addition, A7RC peptides enhanced the inhibitory effects of LIPs on the HUVEC tubular formation on Matrigel. The A7RC-LIPs may be promising drug carriers for anticancer therapy.
You have access to this article
Please wait while we load your content... Something went wrong. Try again?
Article information
DOI
https://doi.org/10.1039/C5BM00161G
Article type
Paper
Submitted
26 May 2015
Accepted
04 Aug 2015
First published
20 Aug 2015
Download Citation
Biomater. Sci., 2015,3, 1545-1554
Author version available
Permissions
A7RC peptide modified paclitaxel liposomes dually target breast cancer
J. Cao, R. Wang, N. Gao, M. Li, X. Tian, W. Yang, Y. Ruan, C. Zhou, G. Wang, X. Liu, S. Tang, Y. Yu, Y. Liu, G. Sun, H. Peng and Q. Wang,Biomater. Sci., 2015, 3, 1545DOI: 10.1039/C5BM00161G
To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.
If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.
If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.
Read more about how to correctly acknowledge RSC content.